Do Mounjaro and Wegovy users regain most of the weight after stopping treatment?

What actually happens in the weeks and months after you stop

Picture the sequence rather than a single moment. In the first week or two off treatment your appetite starts to lift, because the gut-hormone signalling that dampened hunger and slowed your stomach emptying is no longer topped up. Food feels more tempting, portions creep, and the fullness that used to arrive early after a meal takes longer to show up.

Over the following weeks, weight tends to move back upward. This isn't a lack of effort. Weight is a condition shaped by biology, and the body defends a higher set point once the medicine that was overriding those signals is withdrawn. Many people find the return is gradual at first and then steadier, which is why the change can catch you off guard a couple of months in rather than immediately.

How much comes back varies from person to person. Some regain most of what they lost; a smaller number hold onto more of their progress, usually those who have embedded lasting changes to eating and activity. The NHS is clear that these medicines work alongside a reduced-calorie diet and more physical activity rather than instead of them, and that framing matters most at the point you stop. There's a common belief that once the weight is off it stays off, as though the medicine resets something permanently. It doesn't, and letting that idea go early saves a lot of disappointment. You can read more general background in the NHS guidance on obesity treatment including weight-loss medicines.

Why the regain happens at all: the mechanism behind it

Both medicines work by mimicking gut hormones that regulate appetite and blood sugar. Wegovy is a GLP-1 receptor agonist, activating a single pathway. Mounjaro is a dual GIP and GLP-1 receptor agonist, the only dual-agonist weight-management medicine licensed in the UK, hitting two receptors involved in appetite and fullness. Both slow how quickly your stomach empties and increase the sense of having eaten enough.

The key point about regain is that these effects are active, not permanent. They persist while the medicine is in your system and fade as it clears. There's no lasting rewiring of the appetite system that continues once the last dose wears off. So the hunger signals that were being quietened return to their previous strength, and eating drifts back toward where it was before treatment.

This is why clinicians increasingly talk about obesity treatment as long-term management rather than a fixed course, in the same way blood-pressure medicines control pressure while you take them. It's a question our prescribers hear most weeks: people expect a defined end date and are surprised there often isn't a neat one. The trial evidence backs the mechanism directly, showing weight moving in the opposite direction once treatment is withdrawn. Diabetes UK's explanation of how GLP-1 medicines affect appetite and blood sugar is a useful plain-English starting point if you want to understand the biology behind the return.

What the trials show about regain for each medicine

The regain pattern is visible in the same trials that established how well each medicine works. For semaglutide, the STEP programme showed strong average loss on treatment (around 15% over 68 weeks at 2.4mg in STEP 1), and extension work following participants after withdrawal showed substantial regain of the weight lost. For tirzepatide, SURMOUNT-1 reported average reductions of roughly 20 to 21% at the 15mg dose over 72 weeks, with follow-up again showing weight returning once treatment stopped.

Here is a factual side-by-side of the two, drawn from published trials:

Sources: the STEP 1 trial and SURMOUNT-1, both published in the New England Journal of Medicine, and the head-to-head SURMOUNT-1 trial paper on tirzepatide. The comparison figures are averages across thousands of adults, not promises for any one person. Our summary of the SURMOUNT-5 head-to-head results goes deeper on the direct comparison.

Does more loss mean more to regain? Comparing the two on stopping

A fair question follows from the trial numbers. If tirzepatide tends to produce more loss on treatment, does that mean there's more to lose when you stop? In practice the regain pattern is proportional rather than absolute for either medicine. Someone who lost more may see a larger fall in kilograms if they stop abruptly, but the underlying driver, appetite returning, is the same for both drugs.

What the evidence does not support is treating one medicine as a safer bet against regain than the other. Both defend against regain only while you take them. The wider difference between them sits in average effect on treatment and tolerability, not in some lasting protection after withdrawal. Our fuller comparison of weight loss on Wegovy versus Mounjaro lays out where the two genuinely diverge.

People sometimes switch between the two, expecting a fresh burst of loss. That can happen, but a switch is not a reset of the regain risk either. If you've found one isn't delivering, our notes on what to do when Mounjaro isn't working and whether to try Wegovy walk through the realistic options. The honest position is that neither medicine offers a way to bank the loss permanently and walk away, and any provider suggesting otherwise is overselling. The variable that most influences how much you keep is what surrounds the medicine, not which brand is in the pen.

Can you keep the weight off after stopping, and how

Stopping doesn't have to mean losing all your progress, but it takes planning. The strongest position is to treat any pause or stop as a managed transition rather than a hard switch-off. That usually means a prescriber-guided approach, attention to the habits built during treatment, and honesty about the fact that appetite will return.

Practical anchors matter here. Protein adequacy, hydration, fibre and regular strength-based activity all help preserve muscle and manage hunger as the medicine leaves your system. The NHS Better Health resources on sustainable eating and movement are worth leaning on during this phase. None of this replaces the medicine's effect, but it can slow and reduce regain, and it means you're not starting from zero if you and your prescriber decide to restart later.

Some people find a lower maintenance dose, rather than a full stop, suits them better for the long term. Others reach a planned end under a specialist pathway. Because both medicines are managed differently on the NHS, and because private care through a regulated pharmacy follows its own clinical review, the right route depends on your circumstances. If you're weighing up timing between medicines, our guidance on how long to leave between Mounjaro and Wegovy covers the practical waits. The NHS Better Health advice on losing weight and keeping it off is a sensible companion. That last part, keeping it off, is the hard bit. Plan for it.

NHS and access differences that affect how long you stay on

How long you can stay on treatment differs by medicine and by route, and that shapes your regain risk. On the NHS, semaglutide (Wegovy) is recommended under NICE TA875 for a maximum of two years, within a specialist weight management service. That built-in time limit means NHS Wegovy patients will face a planned stop, and the regain question becomes very real at that point.

Tirzepatide reached NHS availability more recently under NICE TA1026, with a phased rollout by BMI and weight-related conditions, and GP practices able to prescribe under the new contract from April 2026, though participation varies by area. NHS access to either is strict and phased, with wrap-around diet and activity support built in. Meeting the criteria doesn't guarantee a place, and waiting lists for specialist services are commonly long. You can read NICE's own position in its recommendation for tirzepatide (TA1026).

Private treatment through a regulated online pharmacy is the alternative for people who don't meet the NHS criteria or don't want to wait. With nume there's no referral and no waiting list, subject to clinical suitability, and no fixed two-year cap dictated by a commissioning rule, though continuation is always re-reviewed clinically. What stays constant across every route is that stopping brings regain risk, so the length of time you can realistically stay on treatment is a legitimate thing to factor into your decision from the start. Our overview of the different weight-loss treatment options and how the consultation works sets out the private route.

How our prescribers help you decide when and whether to stop

None of this is a decision to make alone off the back of an article. At nume, every consultation is read by a GPhC-registered Independent Prescriber the same day, never by software, and that same clinical judgement applies to questions about stopping, tapering or continuing. Your history, how you've responded, tolerability and your goals all feed into it.

Because we don't run subscriptions or auto-renewals, every repeat order is clinically re-reviewed rather than shipped on autopilot, which means there's a natural checkpoint to talk through whether now is the right time to change course. If you're thinking about stepping down a dose, pausing, or switching medicines, a real clinician can map out what to expect and reduce the risk of an abrupt drop-off in effect. You can see who oversees that care on our clinical team profile, and read more about how we work on our page explaining who we are and how we're regulated.

Ozempic and Rybelsus, worth noting since people ask, are both semaglutide but licensed for type 2 diabetes rather than weight loss, so they don't belong in a weight-management stopping plan. For weight management, the licensed options our prescribers work with are Mounjaro and Wegovy. If you want to talk through your own situation, including how to keep progress after treatment, speak to our prescribers and start with a free consultation.

Related questions we've answered

• Wegovy vs Mounjaro: how the two compare overall
• Wegovy vs Mounjaro cost: what a fair comparison looks like
• Why Wegovy might not work as well after Mounjaro
• Switching from Mounjaro to Wegovy: how long to wait